title: Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  Disturbances in the fibrinolytic system are predictors of future cardiovascular events. The aim of this study was to compare plasminogen activator inhibitor 1 (PAI-1) activity and tissue plasminogen activator (tPA) mass concentration between patients with polycystic ovary syndrome (PCOS) and control subjects.
  
  
  METHODS
  One hundred thirty-five patients with PCOS (lean and obese) and 81 healthy controls were recruited for the study. Blood samples for PAI-1 activity and tPA mass were collected together with anthropometric measures.
  
  
  RESULTS
  Obese patients with PCOS displayed increased tPA mass concentration in comparison with controls (p <0.05), and this finding was consistent regardless of whether patients displayed signs of hyperandrogenism or not. When hyperandrogenism was introduced as a prerequisite for the PCOS diagnosis, obese patients with PCOS displayed increased PAI-1 activity as well, p <0.05. Lean patients with PCOS did not differ in terms of PAI-1 activity or tPA mass concentration in comparison to controls.
  
  
  CONCLUSIONS
  Obese women with PCOS have impaired fibrinolysis, in particular if they also display objective biochemical markers of hyperandrogenism.
authors.affiliation: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. asa.lindholm@nll.se
authors.forename: Asa
authors.initials: A
authors.lastname: Lindholm
authors.forename: Marie
authors.initials: M
authors.lastname: Bixo
authors.forename: Mats
authors.initials: M
authors.lastname: Eliasson
authors.forename: Miriam
authors.initials: M
authors.lastname: Hudecova
authors.forename: Ragnheidur
authors.initials: R
authors.lastname: Arnadottir
authors.forename: Jan
authors.initials: J
authors.lastname: Holte
authors.forename: Inger Sundström
authors.initials: IS
authors.lastname: Poromaa
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood / Q000503:physiopathology; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D012044:Regression Analysis; D010959:Tissue Plasminogen Activator / Q000097:blood*
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D010959:Tissue Plasminogen Activator